



ALCMI-006: A Prospective Biospecimen Collection Study from Patients with *ROS1*-Fusion Positive Tumors

Dear Colleague,

This letter is intended to make you aware that one of your patients has expressed an interest in participating in our prospective, fresh biospecimen collection study to generate *ROS1*-fusion positive patient-derived xenograft (PDX) mouse models for individuals with *ROS1*-fusion cancers (NCT03497624). As you know, *ROS1* fusions are detected in ~1% of patients with non-small cell lung cancer as well as in several other types of cancer. Studies of tumors which harbor *ROS1*-fusions are significantly limited by the lack of tumor tissue and validated models to study this type of cancer associated alteration.

I'm writing to you today to describe the study since, if your patient does indeed decide he/she would like to participate and meets the criteria, there will be some tissue collection/handling implications to ensure the cells remain viable for study use. **No response or actions are requested of you at this time.**

Study summary: I serve as the Principal Investigator of ALCMI-006, working within the global research consortium framework of the Addario Lung Cancer Medical Institute (ALCMI, a patient-founded 501c3 public charity) and in collaboration with Champions Oncology Inc. Together, we developed and recently launched ALCMI-006 to generate *ROS1*-fusion positive patient-derived xenograft (PDX) mouse models, including full molecular characterizations such as whole exome sequencing (WES) and RNA sequencing to determine the presence of resistance mutations as well other potential targetable genomic alterations. These patient derived PDX models will have no immediate benefit to your patient. Rather, the resultant renewable tissue resources of PDX models will be broadly shared to help researchers understand mechanisms of response and resistance to therapies, and to assist and facilitate preclinical drug development of new therapies for *ROS1*-fusion positive cancer. Consented participants may donate a portion of their fresh tumor collected during their next clinically-indicated biopsy, surgical procedure or pleural effusion draining. We are only able to receive specimens that are collected under Champions' procedures (we supply the collection kit and instructions) as production of successful models is highly time-sensitive from harvest to engraftment.

If interested in learning more about this study, please view the study website at www.alcmi.net/research/ros1-pdx-study/ or contact the study team at 866-988-*ROS1* (7671) or by email at clinicalops@alcmi.net.

Thank you for your time and consideration! Your assistance is greatly appreciated in order to bring this study of a rare type of lung cancer to fruition!

Sincerely,
Christine M. Lovly, MD, PhD
Associate Professor of Medicine
Vanderbilt-Ingram Cancer Center